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Background: Tigecycline (TIG) is a novel glycylcycline
that was approved in 2005 in the US for treatment of
complicated skin and skin structure infections and compli-
cated intra-abdominal infections. S. aureus (SA), including
methicillin-resistant S. aureus (MRSA), is a leading cause of
skin and skin structure infections. This study examines the
in vitro activity of TIG against SA, including MRSA, over the
last ﬁve years. Additionally, data were stratiﬁed according
to patient location (PL) and specimen source (SS) to deter-
mine if any variation in TIG activity against SA was apparent
among these subpopulations.
Methods: SA isolates were collected from multiple loca-
tions across all nine US Bureau of Census regions during
’03—’04 (N = 1,796), ’05 (N = 1,802), and ’06—’07 (N = 1,800)
and centrally tested using broth microdilution according to
current CLSI standards. TIG activity was analyzed by patient
locations (PL; outpatient [OP], intensive-care unit [ICU], and
inpatient non-ICU [IP]) and by specimen source (SS; blood
[BL], respiratory [RP], and skin and skin structure [SST]).
FDA breakpoints were used to interpret all TIG MIC results.
Results: Against SA overall, TIG had an MIC50/90
of 0.12/0.12mg/L in ’03—’04 and an MIC50/90 of
0.12/0.25mg/L in both ’05 and ’06—’07. Throughout the
study periods, percent susceptibility (%S) of TIG remained
≥99.5%. TIG activity by MIC90 was largely unaffected
by methicillin susceptibility status of the isolate (MIC90:
0.12mg/L for MSSA and 0.25mg/L for MRSA in ’03—’04,
0.25mg/L for MSSA and MRSA in ’05, and ’06—’07). In each
study period, the activity of TIG by MIC90 was identical
among all PL (OP, ICU, and IP) and SS (BL, RP, SST) evalu-
ated relative to TIG activity against SA overall. In the most
recent study period (’06—’07), SA isolates were ≥99% S to
TIG regardless of PL or SS.
Conclusion: By MIC90, TIG in vitro activity was stable
against SA over the past ﬁve years spanning both its devel-
opment and introduction to use and the %S of SA isolates to
TIG remained unaltered and high (>99.5%). TIG activity by
MIC90 was not notably affected by the methicillin suscepti-
bility status of the isolate and was consistent across all PL
and SS evaluated.
doi:10.1016/j.ijid.2008.05.704
44.015
Activity of Telavancin Against Contemporary Streptococ-
cus spp. Pathogens: Recent Results from a European
Surveillance Program (2007)
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Background: -haemolytic streptococci (BHS), viridans
group streptococci (VGS) and Streptococcus pneumoniae
(SPN) are commonly occurring Gram-positive pathogens
responsible for a variety of local and systemic infections.
We evaluated potency of telavancin and comparators against
isolates belonging to these species/groups as part of a global
surveillance protocol for 2007. Telavancin is an investi-
gational, intravenous, semi-synthetic, rapidly bactericidal
lipoglycopeptide broadly active against both aerobic and
anaerobic Gram-positive bacteria and has been evaluated
in two Phase 3 complicated skin and skin structure infection
trials.
Methods: Non-duplicate clinical isolates (1087 total) of
BHS (339), VGS (100) and SPN (648) were submitted from
medical centres in Europe (23), Turkey (2) and Israel (1)
participating in surveillance for 2007. Identiﬁcations were
conﬁrmed by the central monitor and isolates were tested
using CLSI broth microdilution.
Results: Against BHS, SPN and VGS, telavancin potency
was most similar to penicillin (MIC50 values, 0.03 vs
≤0.015—0.06mg/L, respectively) and superior to other com-
parators; all tested isolates were inhibited by ≤0.25mg/L
of telavancin. Telavancin inhibited all VGS and SPN
at ≤0.12mg/L, including penicillin-non-susceptible strains
(27.0% and 30.2%, respectively), and BHS at ≤0.25mg/L.
Telavancin was most active against Group A BHS (MIC90,
0.03mg/L) compared with Groups B and G (0.06 and
0.12mg/L, respectively). All streptococci were suscep-
tible to vancomycin and linezolid, and BHS and VGS
were susceptible to daptomycin. While most strains were
susceptible to levoﬂoxacin (95.0—99.4%), resistance to ery-
thromycin/penicillin were variable (41.0/4.0%, 13.6/0.0%
and 33.6/19.3% for VGS, BHS and SPN, respectively).
Conclusions: Telavancin was broadly active against 2007
European streptococcal isolates. Based on MIC50 values, tela-
vancin was most similar to penicillin in ‘by weight’ activity
against SPN, BHS and VGS (all MICs, ≤0.25mg/L). Continued
monitoring for resistance among Gram-positive cocci will be
critical in assessing long-term efﬁcacy of this potent agent.
doi:10.1016/j.ijid.2008.05.705
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Background: The optochin susceptibility test remains
the primary and in some cases the only method in clini-
